Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated interferon alfa 2a + tenofovir alafenamide
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Pegylated interferon alfa 2a + tenofovir alafenamide is a combination regimen used in the treatment of chronic hepatitis B virus (HBV) infection. Pegylated interferon alfa-2a is an immunomodulatory cytokine receptor agonist that enhances both innate and adaptive immune responses, and tenofovir alafenamide is a nucleotide analog reverse transcriptase inhibitor that suppresses HBV replication by inhibiting the viral polymerase. The combination exploits the immune-stimulating effect of interferon with the direct antiviral potency of tenofovir alafenamide, aiming for higher rates of functional cure (HBsAg loss), especially in hepatitis B e antigen (HBeAg)-positive patients. This regimen offers improved virologic suppression compared to monotherapy, and tenofovir alafenamide has a better renal safety profile than tenofovir disoproxil fumarate. Main indications are chronic hepatitis B virus infection in adults[1][3].
- Other names
- peginterferon alfa-2a + tenofovir alafenamidePegIFN-α2a + TAF
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on pegylated interferon alfa 2a + tenofovir alafenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated interferon alfa 2a + tenofovir alafenamide.